<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718376</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-015</org_study_id>
    <nct_id>NCT04718376</nct_id>
  </id_info>
  <brief_title>A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or&#xD;
      Platinum-Refractory Relapsed Ovarian Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or&#xD;
      Platinum-Refractory Relapsed Ovarian Cancer. At least 30 subjects will be recruited in this&#xD;
      study. The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an&#xD;
      intravenous infusion (IV), every 21 days (q3w, 1 cycle). All patients will receive the&#xD;
      treatment until disease progression, intolerable toxic reaction, death, or withdrawal by&#xD;
      investigator or patient decision (a maximum of 8 cycles). Delays in drug administration is&#xD;
      allowed from the cycle 2, however, the delays should be no more than 3 weeks. Dose&#xD;
      adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>from the initiation of the first dose to 28 days after the last dose，assessed up to 36 months</time_frame>
    <description>The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DoR)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of complete response (DCR)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)</intervention_name>
    <description>All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).</description>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects fully understand and voluntarily participate in this study and sign informed&#xD;
             consent;&#xD;
&#xD;
          2. Age ≥18, female;&#xD;
&#xD;
          3. Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube&#xD;
             carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and&#xD;
             mucous carcinoma);&#xD;
&#xD;
          4. Fail to respond to or progressed on the standard platinum-based therapy ;&#xD;
&#xD;
          5. At least one measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          6. ECOG performance status of 0 to 2;&#xD;
&#xD;
          7. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for&#xD;
             the toxicity without safety risk judged by the investigator, such as hair loss,&#xD;
             hyperpigmentation);&#xD;
&#xD;
          9. Adequate organ function;&#xD;
&#xD;
         10. Subjects of childbearing potential must agree to use effective contraceptive measures.&#xD;
             Female subjects must have a negative pregnancy test before enrolment;&#xD;
&#xD;
         11. Fully comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;&#xD;
&#xD;
          2. Untreated or symptomatic central nervous system (CNS) metastases;&#xD;
&#xD;
          3. Pericardial effusion with clinical symptoms&#xD;
&#xD;
          4. History of allotransplantation;&#xD;
&#xD;
          5. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus&#xD;
             (HIV) or other active viral infection;&#xD;
&#xD;
          6. Serious infection or interstitial pneumonia within 1 week prior to the first dose&#xD;
             administration;&#xD;
&#xD;
          7. Use of other anticancer treatment within 4 weeks prior to the first dose&#xD;
             administration;&#xD;
&#xD;
          8. Enrolled in any other clinical trials within 4 weeks prior to the first dose&#xD;
             administration;&#xD;
&#xD;
          9. Major surgery within 3 months prior to the first dose administration, or have a&#xD;
             surgical schedule during the study period;&#xD;
&#xD;
         10. Thrombosis or thromboembolism within 6 months prior to screening;&#xD;
&#xD;
         11. History of, or known additional malignant tumor within 3 years, except for tumors have&#xD;
             been cured and have not recurred, and carcinoma in situ;&#xD;
&#xD;
         12. Impaired cardiac function or serious cardiac disease;&#xD;
&#xD;
         13. Previous treatment with adriamycin or other anthracyclines, and the total cumulative&#xD;
             dose of prior adriamycin or equivalent is &gt;350 mg/m2.&#xD;
&#xD;
         14. Pregnant or lactating female;&#xD;
&#xD;
         15. Serious and/or uncontrolled systemic diseases;&#xD;
&#xD;
         16. Not suitable for this study as decided by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Zhou, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefang Xia</last_name>
    <phone>010-63932012</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou, Master</last_name>
      <phone>18908384529</phone>
    </contact>
    <investigator>
      <last_name>Qi Zhou, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Xie, Bachelor</last_name>
      <phone>13705932393</phone>
    </contact>
    <investigator>
      <last_name>Rong Xie, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Cancer Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijun Yang, MD</last_name>
      <phone>18977194276</phone>
    </contact>
    <investigator>
      <last_name>Zhijun Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiwei Ouyang, MD</last_name>
      <phone>18275356814</phone>
    </contact>
    <investigator>
      <last_name>Weiwei Ouyang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ge Lou, MD</last_name>
      <phone>13303604488</phone>
    </contact>
    <investigator>
      <last_name>Ge Lou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanlin Luo, Master</last_name>
      <phone>15038373216</phone>
    </contact>
    <investigator>
      <last_name>Yanlin Luo, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiling Li, MD</last_name>
      <phone>13307187507</phone>
    </contact>
    <investigator>
      <last_name>Guiling Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platinum-refractory, platinum-resistant, ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

